Talactoferrin Alfa(NSCLC):到2020年為止的分析與預測 是由出版商GlobalData在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 35 價格從美金2000起跳。
全球非小細胞肺癌(NSCLC)市場在2009年達到40億美金的規模，一般認為到2020年將會達到70憶美金。不但有Avastin及Alimta等領導市場，更有Afatinib、Erbitux、Stimuvax等有潛力開發平台藥物維持市場的成長。Talactoferrin Alfa為Agennix AG的產品，多被研發於許多癌症及嚴重敗血症治療上的口服生技藥物上。
本報告提供全球非小細胞肺癌(NSCLC)市場概要與市場特性，TNM分類，以及Talactoferrin Alfa的概要與作用機制，臨床實驗趨勢，銷售額預測彙整，為您概述為以下內容。
第1章 目錄
第2章 簡介
第3章 NSCLC:市場特性
- NSCLC疾病市場
- 市場預測和年複合成長率
- 推動市場的要素
- 高發病率
- 高死亡率
- 早期NSCLC的化療的使用擴大
- 標靶藥物和維護療法的上市
- 有前途的開發平台藥物
第4章 TNM分類
第5章 Talactoferrin Alfa
- 簡介
- 作用機制
- 臨床實驗
- 影響Talactoferrin Alfa銷售額的因素
- Fast Track Designation
- 高效性
- 低毒性簡介
- 大規模的患者群
- 施打方式的便利性
- 藥物評估
- 銷售額預測
- 目標患者群
- 用量決策
- 市場滲透度
- 年度治療費用
- 銷售額預測
第6章 附錄
圖表
Abstract
Summary
GlobalData's pharmaceuticals report, "Talactoferrin Alfa (NSCLC) - Analysis and Forecasts to 2020" provides Talactoferrin Alfa sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Talactoferrin Alfa including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Talactoferrin Alfa including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2002-2020 for Talactoferrin Alfa in the US, EU-5, Japan
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 Table of contents
1 Table of contents 2
- 1.1 List of Tables 3
- 1.2 List of Figures 3
2 Introduction 4
- 2.1 NSCLC Market 4
- 2.2 Epidemiology 4
- 2.3 Etiology 6
- 2.3.1 Tobacco 6
- 2.3.2 Radiation 7
- 2.3.3 Asbestos 8
- 2.3.4 Air pollution 8
- 2.3.5 Other Environmental Agents 8
- 2.4 GlobalData Pipeline Report Guidance 9
3 NSCLC Disease: Market Characterization 10
- 3.1 NSCLC Disease Market 10
- 3.2 NSCLC Disease Market Forecasts and CAGR 10
- 3.3 Drivers for the NSCLC Disease Market 10
- 3.3.1 High Incidence 11
- 3.3.2 High Mortality Rate 12
- 3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 12
- 3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 12
- 3.3.5 Promising Pipeline Drugs 12
4 Tumor-Node-Metastases (TNM) Classification of NSCLC 13
5 Talactoferrin Alfa 17
- 5.1 Introduction 17
- 5.2 Mechanism of Action 17
- 5.3 Clinical Studies 17
- 5.4 Factors Affecting Sales of Talactoferrin Alfa 18
- 5.4.1 Fast Track Designation 18
- 5.4.2 High Efficacy 18
- 5.4.3 Low Toxicity Profile 18
- 5.4.4 Larger Patient Pool 19
- 5.4.5 Convenient Administration 19
- 5.5 Drug Evaluation 19
- All the drugs are evaluated based on mainly two factors: drug risk benefit score and competition intensity 19
- 5.5.1 Drug Risk Benefit Score 19
- 5.5.2 Intensity of Competition 20
- 5.6 Sales Forecasts 20
- 5.6.1 Target patient Pool of Talactoferrin Alfa 20
- 5.6.2 Dosing 21
- 5.6.3 Market Penetration 21
- 5.6.4 Annual Cost of Therapy 21
- 5.6.5 Sales Forecasts of Talactoferrin Alfa 22
6 NSCLC Market: Appendix 30
- 6.1 Market Definitions 30
- 6.2 Abberiviations 30
- 6.3 Research Methodology 31
- 6.3.1 Coverage 31
- 6.3.2 Secondary Research 31
- 6.3.3 Forecasting 31
- 6.3.4 Number of Patients Approved to take the Drug 32
- 6.3.5 Net Penetration of Drug 32
- 6.3.6 Net Annual Dosing 33
- 6.3.7 Annual Cost of Therapy 33
- 6.3.8 Primary Research 33
- 6.3.9 Expert Panels 33
- 6.4 Drug Sales Estimates Model 34
- 6.5 Contact Us 34
- 6.6 Disclaimer 34
- 6.7 Sources 35
1.1 List of Tables
- Table 1: NSCLC, Incidences and Mortality, 2008-2030 5
- Table 2: NSCLC, TNM Classification, Primary Tumour (T) 14
- Table 3: NSCLC, TNM Classification, Regional Lymph Node (N) 14
- Table 4: NSCLC, TNM Classification, Distant Metastasis (M) 15
- Table 5: NSCLC, TNM Classification 15
- Table 6: Drug Risk Benefit Score of Nexavar 19
- Table 7: Talactoferrin Alfa, NSCLC, Global Sales Forecasts ($m), 2013-2020 22
- Table 8: Talactoferrin Alfa, NSCLC, The US, Sales Forecasts ($m), 2013-2020 23
- Table 9: Talactoferrin Alfa, NSCLC, The UK, Sales Forecasts ($m), 2013-2020 24
- Table 10: Talactoferrin Alfa, NSCLC, France, Sales Forecasts ($m), 2013-2020 25
- Table 11: Talactoferrin Alfa, NSCLC, Germany, Sales Forecasts ($m), 2013-2020 26
- Table 12: Talactoferrin Alfa, NSCLC, Italy, Sales Forecasts ($m), 2013-2020 27
- Table 13: Talactoferrin Alfa, NSCLC, Spain, Sales Forecasts ($m), 2013-2020 28
1.2 List of Figures
- Figure 1: Percentage Distribution of Top 20 Cancers 4
- Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
- Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
- Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
- Figure 6: Total number of cigarettes consumed, The US, 1976-2006 7
- Figure 4: % Share of Risk Factors in Developed Countries 8
- Figure 7: NSCLC, Global, Market Size Forecasts ($bn), 2009-2020 10
- Figure 8: Oncology, Worldwide, Incidence (in million), 2008-2030 11
- Figure 9: NSCLC, Worldwide, Incidence (in million), 2008-2030 11
- Figure 10: NSCLC, Worldwide, Mortality (in million), 2008-2030 12
- Figure 11: Broad Classification of NSCLC 13
- Figure 12: Classification of NSCLC 16
- Figure 13: Clinical Studies of Talactoferrin Alfa 18
- Figure 14: Talactoferrin Alfa, NSCLC, Global Sales Forecasts ($m), 2013-2020 22
- Figure 15: Talactoferrin Alfa, NSCLC, The US, Sales Forecasts ($m), 2013-2020 23
- Figure 16: Talactoferrin Alfa, NSCLC, The UK, Sales Forecasts ($m), 2013-2020 24
- Figure 17: Talactoferrin Alfa, NSCLC, France, Sales Forecasts ($m), 2013-2020 25
- Figure 18: Talactoferrin Alfa, NSCLC, Germany, Sales Forecasts ($m), 2013-2020 26
- Figure 19: Talactoferrin Alfa, NSCLC, Italy, Sales Forecasts ($m), 2013-2020 27
- Figure 20: Talactoferrin Alfa, NSCLC, Spain, Sales Forecasts ($m), 2013-2020 28
- Figure 21: Talactoferrin Alfa, NSCLC, Global, Sales Distribution (%), 2020 29
- Figure 22: Drug Model Diagram 32
- Figure 23: Patients Approved for the Drug 33
|
